An N-glycosylated 60-kDa PV-1 protein that binds heparin was detected in mouse lung from a single mRNA transcript. In the absence of disulfide bond reduction PV-1 is detected as a dimer or large molecular weight oligomer. In the lung of Cav-1, but not Cav-2, null mice the amount of PV-1 protein is diminished, with no detectable change in mRNA level. PV-1 does not fractionate with caveolae on a sucrose density gradient, but the Cav-1 protein is detected in fractions following immunoprecipitation with PV-1 antibodies. Both PV-1 and Cav-1 localize to alveolar endothelial cells, but PV-1 is concentrated at the abluminal and Cav-1 at the luminal cell surface with minimal colocalization. In the Cav-1 null lungs, PV-1 is nearly undetectable in endothelial cells, but remains unchanged in pneumocytes and bronchial epithelial cells. Injection of a VEGF-R2 inhibitor increased PV-1 protein in lung of Cav-1 null, but not Cav-2 or wild-type mice. These data indicate that the PV-1 protein is negatively regulated in pulmonary endothelial cells by VEGF-R2 signaling.
INTRODUCTION
Caveolae are distinct 50 nm plasma membrane invaginations that are biochemically defined by their resident caveolin proteins. [1] [2] [3] A multitude of cell signaling molecules have been localized to caveolae and shown to physically interact with the caveolin proteins via specialized binding motifs. 4 The organization of the plasma membrane into caveolar microdomains is thought to mediate the functional availability of select effector proteins capable of modulating cellular events. 5 Caveolae have been identified in most cell types, but they are most abundant in endothelial cells and the caveolin-1 protein (Cav-1) is essential for their morphogenesis. 6 In the lung, caveolae can be capped by a thin nonmembranous diaphragm and have been termed plasmalemma vesicles. 7 Plasmalemma vesicle protein-1 (PV-1) was isolated from caveolae enriched rat lung membranes and subsequently localized by immunogold electron microscopy to the caveolar diaphragm. 8, 9 No clear role has emerged regarding this diaphragm but it is thought to function as a molecular sieve and is known to bind heparan sulfate proteoglycans. 10, 11 Although PV-1 has been shown to colocalize with the Cav-1 protein, its subcellular distribution is not limited to that of Cav-1. 12 The PV-1 protein has been identified in a number of caveolae enriched cell types such as endothelial and adipocytes but it is also localized to distinct subpopulations of epithelial, neurons and endocrine cells. 13 The PV-1 gene is evolutionarily conserved and has been determined for the rat, mouse and human. Analysis of the PV-1 protein suggests that it translates as a single span trans-membrane anchored protein with a short internal oriented N-terminal domain and an external C-terminal domain containing two long coiled-coil motifs. 14 The rat PV-1 protein is N-glycosylated and can self assemble via disulfide bonding into dimers and larger molecular weight oligomers. 9, 13 Neither the PV-1 gene nor protein has been classified into any known family.
In lung alveoli the endothelium functions in the physiological exchange of oxygen and carbon dioxide. A multitude of pathologies can result in the disruption of alveolar architecture resulting in impair gas exchange that leads to diminished pulmonary function. 15 In the rat lung, both PV-1 and Cav-1 mRNA and protein levels are developmentally regulated with the mature lung expressing the lowest level of detectable transcript and highest concentration of protein. 12 The dynamic changes in PV-1 and Cav-1 expression during postnatal development coincide with alveolar remodeling and maturation of the vascular system and suggest that the coordinate expression of these proteins is important for normal lung development. 16, 17 Caveolae and Cav-1 have been documented as important mediators of endothelial cell function. 5, 18 Several important angiogenic factors have been localized to caveolae and their interaction with Cav-1 can impede activation. 19, 20 We have proposed that the regulation of Cav-1 provides a layer of control by rendering an available pool of effector proteins inactive until the necessary signal triggers their availability. This hypothesis is well suited for the vascular system that is normally quiescent but requires a dynamic readiness to respond to remodeling signals such as injury. Consequently, the loss of Cav-1 and caveolae microdomains results in the loss of this layer of regulation and disruption of cell signaling events that can result in a host of pathologies that include cellular hyper-proliferation and vascular abnormalities. 5, 18 Indeed, both the Cav-1 and Cav-2 null mice exhibit thickened lung alveoli that results in diminished pulmonary function. This lung phenotype is mediated by the loss of Cav-2 as Cav-1 and caveolae persist in the absence of the Cav-2 protein. In these mice there is an increase in the number of VEGF-R2 and Ki67 positive cells, suggesting the development of this phenotype is a consequence of endothelial cell hyper-proliferation. 6, 21 Alternatively, the alveolar thickening observed in these mice may reflect a failed developmental process that normally converts a dual layered endothelium to a single layer. 22 In this manuscript we use the Cav-1 and Cav-2 null mice to evaluate the consequence of caveolae abrogation and the loss of caveolin proteins on the biochemical properties and distribution of the PV-1 protein in the lung.
MATERIAL AND METHODS

Animals.
Cav-1 and Cav-2 null (-/-) mice were generated as previously described. 6, 21 All mice used in these studies were in the C57BL/6J genetic background and maintained by the Albert Einstein College of Medicine (AECOM) barrier facility on a 12 h light/dark cycle with food and water freely available. Mice were genotyped by the polymerase chain reaction (PCR) as previously described. 6, 21 All animal protocols were approved by the AECOM Institute for Animal Studies in compliance with NIH guidelines. Experiments used strain and aged matched adult female mice 6-8 weeks of age.
RT-PCR. The following mouse primer sets were used: PV1 (NCBI Accession #AF348403) sense primer (5'-GCGCAAATGG-GGCTCTCC-3') and anti-sense primer (5'-CACAGGTGGGCGA-TTCTGG-3') amplified a full-length 1370 base pair (bp) product; mCAV-1 (Accession #NM007616) sense primer (5'-ATCACAGCC-CAGGGAAACCTC-3') and anti-sense primer (5'-TATGAGAAT-GGTGGGAATGAA-3') amplified a full-length 725 bp product, RPL19 (Accession #M62952) sense primer (5'-GATCCAATGAGA-CCAATGAA-3') and anti-sense primer (5'-CTCCCGGCGCTT-TCGTGCTTC-3') amplified a 450 bp product. All primer sets span at least one intron-exon boundary. RNA was extracted from lung tissue homogenized in Trizol reagent (GibcoBRL, MD) and reverse transcribed using Superscript II (Gibco) with random hexamers as previously described. 12 Briefly, 1 µg cDNA was subjected to PCR amplification using Taq DNA polymerase (Takara, Japan) for 32 cycles under the following conditions: denaturation 96˚C for 60 seconds, annealing 58˚C for 45 seconds, extension 72 C for 45 seconds. All reactions contained a final concentration of 10% DMSO. Equal volume of PCR product was separated on a 1% agarose gel containing ethidium bromide and molecular weight estimated using a 1 kilobase DNA ladder (Promega, WI).
Production and characterization of goat anti-mouse PV-1 antibody. A 12-amino acid peptide (LPVVNPAAQPSG) corresponding to the extreme C-terminus of the mouse PV-1 (mPV-1) protein (NCBI Accession #AAK20902) was synthesized, with the addition of amino acids CKG to the N-terminus to enhance solubility, conjugated to keyhole limpet hemocyanin and used to generate antibodies in goat (Bethyl Labs, TX). Antibodies were peptide-affinity purified and evaluated for specificity in Western blot. The goat-anti-mPV-1 antibodies detect a predominant 60-kDa (reduceddenatured) and 120-kDa band (denatured only) from mouse lung tissue by Western blot (see Fig. 2 ). Antibody pre-absorption with peptide completely blocked detection of mPV-1 bands and pre-bleed goat serum resolved no detectable protein (data not shown). No cross reactivity was observed with PV-1 protein from rat lung or Cos-1 cell expressing a cloned rat PV-1 (rPV-1) protein (data not shown; 4 of 12 amino acid mismatch between rat and mouse peptide antigen; refs. 12 and 13).
Western blotting. Lung tissue was Dounce homogenized in MBS extraction buffer (25 mM MES-buffered saline; pH 6.5) with 60 mM n-octyl glucoside, 1% Triton X-100 and a protease inhibitor cocktail [Complete-Mini (Roche, IN), 1mM phenymethylsulfonylfluoride (PMSF), 0.2 mM sodium-vanadate, and 5 mM NaF] then passed through a 20 µm nylon mesh. Protein concentration of lung extract was determined by BCA assay (Pierce, IL) and 30 µg of protein boiled in SDS sample buffer (denatured) with 300 mM DTT (reduced). Proteins were resolved by SDS-PAGE (4/12.5% discontinuous polyacrylamide gel) and transferred to nitrocellulose (0.2 µm). Blots were blocked with Carnation 2% nonfat powdered dry milk (Nestle, PA) for 2h in TBST [10 mM Tris-HCL (pH 8.0), 150 mM NaCl, and 0.2% Tween-20]. Membranes were washed and incubated with antibodies diluted in TBST containing 5% BSA (Sigma-Aldrich, MO). Primary antibodies for 3h: 1) goat-antimPV-1 (1:3000), 2) mouse-anti-Cav-1 (mAb 2297, BD-Transduction Labs, CA; 1:1000), 3) mouse-anti-Cav-2 (mAb 65, BD-Transduction Labs, 1:1000) or 3) mouse-anti-β-actin (mAb AC15, Sigma; 1:10,000). Secondary HRP-conjugated antibodies for 1h: 1) donkey anti-goat (Jackson ImmunoResearch, PA; 1:300,000) or goat-antimouse (Pierce; 1:10,000). Proteins were detected using an enhanced chemiluminescence (ECL) detection kit (Supersignal; Pierce).
N-linked deglycosylation. Mouse lung tissue (50 µg) or Cos-1 cells transiently transfected with a rat PV-1 plasmid 12 were homogenized as described in MBS extraction buffer. A protein denaturation buffer (10X = 0.5% SDS with 1% β-mercaptoethanol) was added to lysates and boiled for 10 minutes. Denatured glycoprotein was then incubated with 250 units of N-Glycosidase-F (PNGase F; New England Biolabs, MA) in G7 reaction buffer (10X = 50 mM Sodium Phosphate, pH 7.5) supplemented with 1% NP-40 for 1 hour at 37˚C. The de-glycosylation of RNase B was used as a control substrate (data not shown). De-glycosylated lysates were combined with SDS sample buffer containing DTT, boiled and proteins separated by SDS-PAGE, transferred to nitrocellulose and Western blotting using goat-anti-mPV-1 performed as described.
Heparin affinity chromatography. Lung tissue was homogenized in MBS extraction buffer and protein concentration determined by BCA assay as described. A 25 mM MES starting buffer containing 1.0 mM NaCl (pH 6.5) was used to condition 1ml Heparin affinity columns (Amersham-Pharmacia, NJ) and dilute samples to 400 µg/ml of protein. Lung protein lysates were passed three times through a column and unbound protein fraction collected. The column was further washed with five column volumes of starting buffer to elute any remaining unbound protein. A discontinuous 0.05, 0.75, 1.50, 3.00 M NaCl-25 mM MES salt gradient (elution buffer, pH 6.5) was used to elute 1ml fractions of Heparin-bound proteins. Between each salt exchange the column was washed with three volumes of the elution buffer to remove any residual unbound protein. Equal amount of protein from fractions were subjected to SDS-PAGE, transferred to nitrocellulose and Western blotted for the mPV-1 protein as described.
Immunoprecipitation. Immunoprecipitation was carried out using Protein-G-Sepharose 4B-FF (Sigma-Aldrich). Briefly, lung tissue (~200 mg wet weight) was excised and homogenized in MBS extraction buffer as described above and lysate (Ctrl) precleared with Protein-G-sepharose beads for 30 minutes at 4˚C. The cleared lysates were then incubated with goat-anti-mPV-1 prebound to Protein-G-sepharose for 1 h at 4˚C. Lysates were centrifuged at 900 rpm for 10 minutes and the resultant beads (IP) and supernatant (UNB) separated. The beads were repeatedly washed then suspended in SDS-sample buffer containing 0.3M DTT, boiled, centrifuged and supernatant separated by SDS-PAGE and proteins transferred to nitrocellulose membrane. Western blotting was performed using goat-a-mPV-1 and a monoclonal anti-CAV-1 (2297; Transduction Labs) as described.
Preparation of caveolae-enriched membrane fractions. Lung tissue (200 mg) was excised rinsed in ice-cold MBS then Dounce homogenized in 1 ml MBS extraction buffer. Lung extract was mixed with an equal volume of 80% sucrose solution prepared in MBS to a final concentration of 40% sucrose and placed at the bottom of a 12 ml ultracentrifuge tube. A 5/30% discontinuous sucrose gradient was layered on top of the homogenate. Samples were centrifuged at 39,000 rpm for 16h in an SW41 rotor (Beckman Coulter, CA) as previously described. 23 A light scattering band was observed at the 5-30% interface and twelve 1 ml fractions collected from the top of each gradient. Equal amounts (50 µl) from each fraction were separated by SDS-PAGE and subjected to Western blot analysis as described.
Immunofluorescence. Mice were transcardiac perfused with 4% paraformaldehyde, lungs were removed, fixed for an additional 1 h, transferred to 30% sucrose until sunk then cryosectioned at 5 µm and collected on glass slides. Briefly, sections were exposed to 0.2% saponin (Sigma-Aldrich) for 30 min, washed, blocked in 10% BlokHen-II for 1h then incubated in primary antibodies containing 5% normal donkey serum with 0.2% IgG-free BSA for 3 h. Sections were washed and incubated with donkey secondary antibodies: (1) FITC-conjugated donkey anti-goat-IgG or (2) CY3-conjugated donkey anti-rabbit-IgG in PBS with 0.2% BSA and DAPI for 1 h. Sections were coverslipped using Prolong Gold anti-fade (Molecular Probes, OR) reagent. Images were captured using an Olympus IX80 microscope equipped with a 60X plan Neofluar objective and Photometrics cooled CCD camera and processed using IP lab software (Vay Tek Inc., IA).
VEGF inhibition. Cohorts (n = 4) of six-week old female wild-type, Cav-1, and Cav-2 null mice were given twice daily 200 µM intraperitonel (i.p.) injections for three days of vascular endothelial growth factor (VEGF) inhibitor-V1 (Calbiochem, CA) or dimethyl sulfoxide (DMSO) as control. Mice were sacrificed, lungs excised and processed for PV-1 Western blotting and RT-PCR as described above.
Computation of PV-1 protein sequence. Protein motif identification was done using Prosite (www.expasy.org/prosite/) 24 and PSORT-II (http://psort.ims.u-tokyo.ac.jp/). 25 null mice by RT-PCR ( Fig. 1; top panel) . As expected a full-length Cav-1 transcript (725 bp) was detected in the lung of wild-type, but not Cav-1 null mice ( Fig. 1 ; middle panel). RPL19 was used as an internal control ( Fig. 1 ; bottom panel) to normalize for total lung cDNA. There was no difference in the level of PV-1 transcript detected in the lung of wild-type or Cav-1 null mice ( Fig. 1; top  panel) .
RESULTS
Equivalent
PV-1 protein is diminished in lung of Cav-1 null mice. The PV-1 protein is detected as a ~60-kDa protein in the mouse lung following disulfide reduction (DTT) and denaturation by boiling ( Fig. 2; reduced-denatured) . In the absence of disulfide reduction PV-1 is detected at higher molecular weight with predominant bands at 120-and ≥ 220-kDa ( Fig. 2; denatured) . As expected, α-and β-Cav-1 protein isoforms (~22-and 18-kDa, respectively) were detected in lung from wild-type, but not Cav-1 mice ( Fig. 2; middle panel) . The level of β-actin was used for protein normalization of lung extract following separation by SDS-PAGE ( Fig. 2 ; bottom panel). In the lung of Cav-1 null mice the PV-1 protein is diminished (~8-fold) as compared to wild-type ( Fig. 2; reduced-denatured) .
PV-1 is N-glycosylated and binds heparin. The hydrolysis of N-glycan chains by the amidase N-glycosidase-F completely shifts the molecular weight of 60-kDa PV-1 to ~50-kDa (Fig. 3A) . No difference in glycosylation status of PV-1 was observed between wild-type ( Fig. 3A ; left panel) and Cav-1 null ( Fig. 3A; middle panel) . Similarly, the rat PV-1 plasmid produced a protein doublet in Cos-1 cells that represent an N-glycosylated 60-kDa and nonglycosylated 50-kDa PV-1 ( Fig. 3A ; right panel). Moreover, like rat PV-1, 13 mouse PV-1 also binds to heparin with a high affinity requiring ≥ 0.75 M NaCl for elution from a heparin affinity column (Fig. 3B ).
PV-1 protein level is unchanged in lung of Cav-2 null mice. The 60-kDa PV-1 protein is detected in lung of Cav-2 null mice at levels equivalent to wild-type by Western blot ( Fig. 4A; top panel) . As expected, the Cav-1, but not Cav-2, protein was detected in the Cav-2 null ( Fig. 4A ; middle panels). β-actin levels remained unchanged and were used for protein normalization ( Fig. 4A ; bottom panel). No change in the level of PV-1 mRNA was detected by RT-PCR in Cav-2 null mice (Fig. 4B) . The degree of N-glycosylated 60-kDa PV-1 in the Cav-2 null is similar to that of wild-type mice (Fig. 4C) .
PV-1 does not fractionate with membrane caveolae. The majority of PV-1 protein from the lung of wild-type ( Fig. 5; top panel) and Cav-1 null ( Fig. 5 ; middle panel) mice separate into the protein rich fractions (≥ fraction 7) following density separation on a sucrose gradient. A faint band of PV-1 was detected in the caveolae/Cav-1 enriched fraction-4 of wild-type ( Fig. 5; top panel) , but not Cav-1 null mouse lung ( Fig. 5 ; middle panel). Unlike PV-1, the bulk of Cav-1 from wild-type lung partitions into the caveolae-lipid rich sucrose fraction-4 and -5 ( Fig. 5 ; lower panel). Similar results were obtained with lung fractions from Cav-2 null mice (data not shown).
PV-1 is localized to pulmonary endothelial cells and is concentrated at the abluminal surface with minimal Cav-1 colocalization.
Strong PV-1 immunofluorescence was detected in alveolar endothelial cells at the abluminal cell surface in parallel with the basement membrane ( Fig. 6; white arrows) . In contrast, Cav-1 localization was PV-1 in Cav-1 Null Lungs concentrated at the luminal cell surface ( Fig. 6 ; red arrows), juxtaposed to the PV-1 signal. However, limited PV-1 and Cav-1 colocalization was detected in some cells with the strongest signal concentrated around the perinuclear region ( Fig. 6D; blue arrows) .
PV-1 is expressed by some alveolar pneumocytes and bronchial epithelial cells. The discrete localization of Cav-1 in the lung vividly reveals the underlying alveolar capillary beds ( Fig. 6; red arrows) . Although PV-1 labels pulmonary endothelial cells additional signal is detected in many alveolar pneumocytes and bronchial epithelial cells (Fig 6  and Fig. 7) ; green arrows).
PV-1 is reduced in pulmonary endothelial cells of Cav-1 null mice. The polarized distribution of PV-1 (white arrows) and Cav-1 (red arrows) in endothelial cells of wild-type mouse lung (Fig. 6) is revealed by combined immunofluorescence. No Cav-1 was detected in the lung of Cav-1 null mice (Fig. 7) . Moreover, PV-1 immunofluorescence was visibly reduced in morphologically identifiable capillary endothelial cells from Cav-1 null mice ( Fig. 7 ; white arrows) with little change in PV-1 positive alveolar pneumocytes or bronchiole epithelial cells ( Fig. 7; green arrows) . The cellular and subcellular pattern of PV-1 localization in the lung of Cav-2 null mice was similar to that observed in wild-type (data not shown). PV-1 shows a weak biochemical interaction with Cav-1. The PV-1 protein is immunoprecipitated from lung of both wild-type ( Fig. 8A ; left panel) and Cav-1 null ( Fig. 8A ; right panel) mice. The majority of the Cav-1 protein in wild-type lung is not biochemically associated with the PV-1 protein, but remains concentrated in the unbound fraction following immunoprecipitation with PV-1 antibodies ( Fig. 8B; UNB) . However, some α-Cav-1 isoform was detected (~30% total) in the immunoprecipitate fraction ( Fig. 8B; IP) showing limited association with PV-1.
PV-1 is negatively regulated by VEGF-R2 in the lung of Cav-1 null mice. Cav-1 null mice treated with VEGF inhibitor-V1 showed an increase in the level of detectable PV-1 protein (~5-fold relative to untreated; Fig. 9 ; top panel). In contrast, wild-type mice injected with VEGF inhibitor-V1 showed no detectable change in the level of PV-1 ( Fig. 9; top panel) or Cav-1 proteins in the lung (Fig 9; middle panel) . As expected no detectable Cav-1 protein was observed in Cav-1 null mice. The protein β-actin served as normalization Fig. 9; bottom panel) .
PV-1 in
Putative PV-1 protein motifs. Analysis of the PV-1 protein sequence revealed three new sequence motifs that are conserved among the mouse, rat and human sequences (Fig. 10) . Most notably is a consensus Cav-1 binding motif φxφxxxxφ at residues 21-28 (φ represents an aromatic amino acid and x any residue) situated proximal to the transmembrane domain (residues 29-46) within the short internal oriented N-terminal domain of the mouse PV-1 protein. In addition, the mouse (residues 189-205) and human (residues 355-371) PV-1 proteins have a bipartite nuclear targeting sequence (NTS). All three species show a strong conservation of residues around the mouse NTS with the rat and human sequence lacking only one of the final three consensus Arg or Lys residues of the prototypical NTS motif. 26 The C-terminal domain of the PV-1 protein is proline-rich and contains a number of core SH3-binding peptide motifs (Pro-Xaa-Xaa-Pro), one (residues 408-411) that is conserved between all three species. The mouse PV-1 protein contains a total of four PXXP motifs with one true consensus SH3-binding class-II (Xaa-Pro-Xaa-Xaa-Pro-Xaa-Arg) peptide sequence beginning at residue 392. The rat and human PV-1 proteins contain six and four PXXP motifs respectively. 27 
DISCUSSION
In this report we generate and characterize a novel antibody that was used to identify a 60-kDa PV-1 glycoprotein from mouse lung that forms disulfide sensitive dimers and oligomers in situ. Biochemically, our PV-1 antibodies can immunoprecipitate α-Cav-1, but PV-1 does not cofractionate with caveolae on a sucrose density gradient. Additionally, we demonstrate PV-1 expression in alveolar endothelial cells, pneumocytes and bronchial epithelial cells. Moreover, we show that the majority of PV-1 is concentrated on the abluminal surface of endothelial cells juxtaposed to the luminal distribution of Cav-1 with minimal colocalization of these two proteins. Here we use the Cav-1 null mouse to evaluate the consequence of caveolae abrogation on the expression and localization of the PV-1 protein. The loss of Cav-1 results in reduced PV-1 expression by pulmonary endothelial cells but remains unchanged in the other lung cell types. We show that the PV-1 protein is negatively regulated by VEGF-R2 in the lung of Cav-1, but not Cav-2, null mice.
Our immunofluorescence data shows PV-1 immunoreactivity localized to the abluminal surface of endothelial cells in a discrete band that runs parallel with the basement membrane. This is in contrast to the strong detection of Cav-1 on the luminal side of lung endothelial cells. Interestingly, there is a biochemical heterogeneity of caveolae -plasmalemma vesicles between the abluminal and luminal cell surfaces with the majority of plasmalemma vesicles described as resident to the abluminal surface of endothelial cells in many tissues. 10, 28 Although there does appear to be limited colocalization of these two proteins in situ, consistent with what we have observed with rat PV-1, 12 additional studies that allow for higher resolution will be necessary to determine the extant of their overlap.
Although our immuno-and bio-chemical data confirms PV-1 interaction with Cav-1 it reveals an irregular subcellular pattern in situ. This may reflect a transient interaction mediated by direct or indirect protein interactions that result in differential targeting to select intracellular compartments. This episodic association of PV-1 with Cav-1 may reflect a broader interaction of PV-1 with protein complexes. Indeed, the extreme C-terminus of the PV-1 protein is rich in a core PXXP motif that can interact with proteins that contain Src homology domain-3 (SH3) sequence. Functionally, SH3-domain containing proteins and their cognate adaptors mediate protein-protein interaction and modulate cell signaling events. 29 The interaction of PV-1 with select SH3 proteins may regulate the subcellular localization and modulate the activity of PV-1 protein aggregates. Future studies will need to empirically verify PV-1 interaction with various SH3-domain containing proteins and evaluate the functional importance of such interaction on cellular events.
It is expected that the two C-terminal coiled-coil domains would confer a linear rod-like structure to the PV-1 protein. 30 The formation of DTT sensitive oligomeric PV-1 filaments in situ with proline-rich ends capable of recruiting SH3-domain protein aggregates provokes an interesting molecular structure. Many of the coiled-coil protein classes such as intermediate filaments (IF), the nuclear lamins, motor proteins and Golgins provide an interesting basis for speculative comparison on a broader role for PV-1 as a component of various molecular scaffolds. 30, 31 Indeed, PV-1 appears to be a component of the diaphragm of caveolae and fenestrae, 32 yet it is clear that Cav-1 is not essential for formation of diaphragm fenestrae. 33 Given the disparate cellular and intracellular distribution of the PV-1 and Cav-1 proteins in the mouse lung it is not surprising that the abrogation of caveolae/Cav-1 does not result in the complete loss of PV-1. The lung of Cav-1, but not Cav-2, null mice has significantly less overall PV-1 protein despite a similar hyper-cellularity. Both Cav-1 and Cav-2 null mice exhibit thickened alveolar septa as a consequence of an increase in basement membrane and cell number. Specifically there is an increase in proliferation antigen Ki67 and VEGF-R2 positive cells suggesting hyper-proliferation of endothelial cells. 6, 21 The generation of Cav-2 null mice showed that it was the loss of Cav-2, not Cav-1, protein that was responsible for the aberrant lung phenotype in both genetic models. Indeed, the loss of Cav-1 results in the loss of Cav-2 by proteolytic degradation as a result of failed hetero-dimerization with Cav-1. In contrast the loss of Cav-2 has little effect on Cav-1 protein or caveolae biogenesis. 5, 21 Consequently, Cav-1 mediated protein interaction and targeting remains intact in the Cav-2 null mouse and likely explain the difference in PV-1 protein levels between these two genetic models. This underscores select differences in pulmonary endothelial cells between the Cav-1 and Cav-2 null mice, demonstrating a distinct biochemical deficit in the Cav-1 null lung despite a similar morphological phenotype to that of Cav-2 null mice.
One possible mechanism could be a persistent and elevated VEGF signal in the lung of Cav-1 null mice that might developmentally skew endothelial cells toward a proliferative phenotype and away from terminal differentiation. While the expression of VEGF is essential for survival 34, 35 its overexpression in the lung of transgenic mice promotes alveolar remodeling. 36, 37 Indeed, VEGF receptor inhibition during neonatal development promotes simplified vasculoalveolar morphology, 38 whereas in the adult there is an increase in endothelial apoptosis and concomitant vascular regression. 39 Hence, a developmental switch occurs in mice around four-weeks of age that converts the action of VEGF from an essential proactive vasculoangiogenic factor to a more reactive angiogenic compound that affect preexisting vasculature.
Accumulating evidence implicates Cav-1 as a negative regulator of ligand mediated cell signaling via sequestration of cognate receptors in caveolae microdomains on the cell surface. 5, 18 We show that a dysregulation in VEGF signaling in endothelial cells was in part responsible for the reduction of the PV-1 protein. Indeed, injection of the VEGF-R2 inhibitor-V1 heptapeptide, which has been shown to inhibit VEGF-induced endothelial cell proliferation in vitro and angiogenesis in vivo, [40] [41] [42] in Cav-1 null but not wild-type or Cav-2 null mice, increased PV-1 protein level. Although the levels of PV-1 did not return to those of wild-type mice this may reflect the nature of our injection regime.
Our data strongly suggests that a hyper-activation of VEGF-R2 is responsible for the decreased level of PV-1 protein in Cav-1 null lung. Consistent with the negative regulation of PV-1 by VEGF, Abdollahi et al. have shown that human PV-1 gene expression is upregulated by the anti-angiogenic protein endostatin in endothelial cells. 43 These changes may be mediated by transcriptional regulation that is undetectable by our PCR as a consequence of whole tissue extraction and inclusion of various cellular sources of PV-1 that dilute out changes observed in VEGF responsive endothelial cells. Indeed, the variation in PV-1 protein ratios may reflect the disparate cell origins and nonuniform distribution of PV-1 in pooled lung extract. It is unclear if there is an upregulation of VEGF in the lung of Cav-1 null mice or if the loss of caveolae/Cav-1 results in the dysregulation of VEGF-R2 and ligand independent activation. Moreover, these data indicate that when VEGF levels are elevated, PV-1 levels are decreased and this inverse relationship suggests PV-1 is associated with a more quiescent differentiated endothelial cell phenotype. Figure 10 . PV-1 protein sequence analysis and localization of putative functional motifs. Alignment of PV-1 sequences from mouse, rat and human with conserved amino acids and predicted motifs are illustrated.
